RVMD Q4 2021 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+8.1% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$53M-559.3% margin

Net Income

-$53M-556.8% margin

EPS (Diluted)

$-0.71

QoQ Revenue Growth

+759.2%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$40M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$738M

Total Liabilities

$135M

Stockholders' Equity

$603M

Cash & Equivalents

$108M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$9M	+8.1%
Gross Profit	$9M	$9M	+8.1%
Operating Income	-$53M	-$34M	-55.3%
Net Income	-$53M	-$34M	-54.0%

Revenue Segments

Collaboration Revenue Member

$9M100%